AHCO:NSD-AdaptHealth Corp (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 9.65

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

STA Verdict

Verdict

About

AdaptHealth, LLC distributes home medical equipment. The Company offers mobility products, respiratory therapy, non- invasive ventilation, nutrition supplies, ocean home health products, sleep therapy supplies, bed lifts, seat lift chairs, and bath aids. AdaptHealth, LLC was founded in 2012 and is based in Phoenixville, Pennsylvania.

Market Stats

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-12-07 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

N/A

USD21.73B 52.93 37.11
PODD Insulet Corporation

N/A

USD11.37B 713.02 139.49
ABMD Abiomed, Inc

N/A

USD8.54B 39.50 30.56
BRKR Bruker Corporation

N/A

USD7.76B 38.49 21.71
IART Integra LifeSciences Holdings ..

N/A

USD5.35B 90.74 18.19
LIVN LivaNova PLC

N/A

USD4.09B 77.40 40.33
NUVA NuVasive, Inc

N/A

USD3.89B 83.15 18.04
WMGI Wright Medical Group N.V

N/A

USD3.75B N/A 45.23
TNDM Tandem Diabetes Care, Inc

N/A

USD3.62B N/A -283.81
CNMD CONMED Corporation

N/A

USD3.24B 113.33 24.71

ETFs Containing AHCO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.70B 71% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 10.21 30% F 36% F
EV/EBITDA 8.08 30% F 35% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 19.75% 84% B 88% B+
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 112.20% 15% F 19% F
Technical Ratios  
Short Ratio 3.05 63% D 57% F
Short Percent 3.38% 68% D+ 53% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector